PL4041733T3 - Pochodne mające ugrupowanie 2,3-dihydro-1h-indenu lub 2,3-dihydrobenzofuranu lub ich farmaceutycznie dopuszczalne sole oraz kompozycje farmaceutyczne je zawierające - Google Patents
Pochodne mające ugrupowanie 2,3-dihydro-1h-indenu lub 2,3-dihydrobenzofuranu lub ich farmaceutycznie dopuszczalne sole oraz kompozycje farmaceutyczne je zawierająceInfo
- Publication number
- PL4041733T3 PL4041733T3 PL20887669.8T PL20887669T PL4041733T3 PL 4041733 T3 PL4041733 T3 PL 4041733T3 PL 20887669 T PL20887669 T PL 20887669T PL 4041733 T3 PL4041733 T3 PL 4041733T3
- Authority
- PL
- Poland
- Prior art keywords
- mountry
- dihydrobenzofuran
- indene
- dihydro
- derivatives
- Prior art date
Links
- HBEDSQVIWPRPAY-UHFFFAOYSA-N 2,3-dihydrobenzofuran Chemical compound C1=CC=C2OCCC2=C1 HBEDSQVIWPRPAY-UHFFFAOYSA-N 0.000 title 2
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 title 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20190146679 | 2019-11-15 | ||
| PCT/KR2020/015864 WO2021096238A1 (en) | 2019-11-15 | 2020-11-12 | Novel derivatives having 2,3-dihydro-1h-indene or 2,3-dihydrobenzofuran moiety or pharmaceutically acceptable salt thereof and pharmaceutical compositions comprising the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL4041733T3 true PL4041733T3 (pl) | 2024-09-23 |
Family
ID=75911374
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL20887669.8T PL4041733T3 (pl) | 2019-11-15 | 2020-11-12 | Pochodne mające ugrupowanie 2,3-dihydro-1h-indenu lub 2,3-dihydrobenzofuranu lub ich farmaceutycznie dopuszczalne sole oraz kompozycje farmaceutyczne je zawierające |
Country Status (12)
| Country | Link |
|---|---|
| EP (2) | EP4041733B1 (pl) |
| JP (2) | JP7671751B2 (pl) |
| KR (1) | KR20210059632A (pl) |
| CN (2) | CN118955495A (pl) |
| AU (1) | AU2020384066B2 (pl) |
| BR (1) | BR112022009409A2 (pl) |
| CA (1) | CA3154313A1 (pl) |
| ES (1) | ES2984255T3 (pl) |
| MX (1) | MX2022005679A (pl) |
| PL (1) | PL4041733T3 (pl) |
| RS (1) | RS65662B1 (pl) |
| WO (1) | WO2021096238A1 (pl) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL273428B2 (en) | 2017-09-22 | 2023-09-01 | Jubilant Epipad LLC | Heterocyclic compounds as pad inhibitors |
| AU2018352142B2 (en) | 2017-10-18 | 2022-08-25 | Jubilant Epipad LLC | Imidazo-pyridine compounds as PAD inhibitors |
| CA3080677A1 (en) | 2017-11-06 | 2019-05-09 | Jubilant Prodel LLC | Pyrimidine derivatives as inhibitors of pd1/pd-l1 activation |
| SMT202400203T1 (it) | 2017-11-24 | 2024-07-09 | Jubilant Episcribe Llc | Composti eterociclici come inibitori di prmt5 |
| MX2020009517A (es) | 2018-03-13 | 2021-01-20 | Jubilant Prodel LLC | Compuestos biciclicos como inhibidores de la interaccion/activacio n de pdl/pd-l1. |
| EP4308561A4 (en) * | 2021-05-11 | 2025-01-22 | Yuhan Corporation | COMPOUNDS HAVING INHIBITING ACTIVITY AGAINST GLUCOSYLCERAMIDE SYNTHASE OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THEREOF |
| KR20240035820A (ko) | 2021-07-09 | 2024-03-18 | 플렉시움 인코포레이티드 | Ikzf2를 조절하는 아릴 화합물 및 약학 조성물 |
| WO2024090917A1 (en) * | 2022-10-24 | 2024-05-02 | Yuhan Corporation | Novel salt of dimethyl-2,3-dihydro-1h-indene derivative and processes for preparing the same |
| AU2023368362A1 (en) * | 2022-10-24 | 2025-03-20 | Green Cross Corporation | Improved processes for preparing dimethyl-2,3-dihydro-1h-indene derivatives |
| WO2025032129A1 (en) | 2023-08-08 | 2025-02-13 | Syngenta Crop Protection Ag | Novel aminoindane and aminotetraline compounds |
| WO2025159544A1 (en) * | 2024-01-26 | 2025-07-31 | Yuhan Corporation | Pharmaceutical composition for preventing or treating gaucher disease |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9600683D0 (sv) | 1996-02-23 | 1996-02-23 | Astra Ab | Azabicyclic esters of carbamic acids useful in therapy |
| US6953855B2 (en) * | 1998-12-11 | 2005-10-11 | Targacept, Inc. | 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof |
| GB0400812D0 (en) | 2004-01-14 | 2004-02-18 | Celltech R&D Ltd | Novel compounds |
| WO2006053043A2 (en) | 2004-11-10 | 2006-05-18 | Genzyme Corporation | Methods of treating diabetes mellitus |
| EP2594565B1 (en) | 2007-05-31 | 2018-10-24 | Genzyme Corporation | 2-acylaminopropanol-type glucosylceramide synthase inhibitors |
| WO2009117150A2 (en) | 2008-03-20 | 2009-09-24 | Genzyme Corporation | Method of treating lupus with ceramide derivatives |
| JP2011529500A (ja) | 2008-07-28 | 2011-12-08 | ジェンザイム コーポレーション | 虚脱性糸球体症および他の糸球体疾患の処置のためのグルコシルセラミドシンターゼ阻害 |
| WO2010091164A1 (en) * | 2009-02-06 | 2010-08-12 | Exelixis, Inc. | Inhibitors of glucosylceramide synthase |
| WO2010091104A1 (en) * | 2009-02-06 | 2010-08-12 | Exelixis, Inc. | Glucosylceramide synthase inhibitors |
| CN107080747B (zh) * | 2011-03-18 | 2021-02-26 | 建新公司 | 葡萄糖基神经酰胺合酶抑制剂 |
| US8961959B2 (en) * | 2011-10-17 | 2015-02-24 | The Regents Of The University Of Michigan | Glucosylceramide synthase inhibitors and therapeutic methods using the same |
| JOP20130273B1 (ar) | 2012-09-11 | 2021-08-17 | Genzyme Corp | مثبطات انزيم (سينثاز) غلوكوسيل سيراميد |
| CN105745206B (zh) * | 2013-09-20 | 2019-08-13 | 生物马林药物股份有限公司 | 用于治疗疾病的葡萄糖神经酰胺合成酶抑制剂 |
| WO2019079626A1 (en) * | 2017-10-19 | 2019-04-25 | Samumed, Llc | 6- (HETEROARYL 5-CHAIN) ISOQUINOLIN-3-YL CARBOXAMIDES, THEIR PREPARATION AND THEIR USE |
-
2020
- 2020-11-12 PL PL20887669.8T patent/PL4041733T3/pl unknown
- 2020-11-12 CA CA3154313A patent/CA3154313A1/en active Pending
- 2020-11-12 JP JP2022527911A patent/JP7671751B2/ja active Active
- 2020-11-12 RS RS20240700A patent/RS65662B1/sr unknown
- 2020-11-12 EP EP20887669.8A patent/EP4041733B1/en active Active
- 2020-11-12 ES ES20887669T patent/ES2984255T3/es active Active
- 2020-11-12 CN CN202410840972.5A patent/CN118955495A/zh active Pending
- 2020-11-12 BR BR112022009409A patent/BR112022009409A2/pt unknown
- 2020-11-12 AU AU2020384066A patent/AU2020384066B2/en active Active
- 2020-11-12 KR KR1020200150785A patent/KR20210059632A/ko active Pending
- 2020-11-12 CN CN202080075084.9A patent/CN114829361B/zh active Active
- 2020-11-12 EP EP24163536.6A patent/EP4389744B1/en active Active
- 2020-11-12 WO PCT/KR2020/015864 patent/WO2021096238A1/en not_active Ceased
- 2020-11-12 MX MX2022005679A patent/MX2022005679A/es unknown
-
2025
- 2025-04-21 JP JP2025069586A patent/JP2025111591A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4041733C0 (en) | 2024-05-08 |
| US20230002379A1 (en) | 2023-01-05 |
| CN114829361A (zh) | 2022-07-29 |
| CA3154313A1 (en) | 2021-05-20 |
| BR112022009409A2 (pt) | 2022-08-09 |
| JP2023503830A (ja) | 2023-02-01 |
| ES2984255T3 (es) | 2024-10-29 |
| RS65662B1 (sr) | 2024-07-31 |
| EP4389744B1 (en) | 2025-12-03 |
| EP4389744A1 (en) | 2024-06-26 |
| AU2020384066A1 (en) | 2022-04-21 |
| CN114829361B (zh) | 2024-07-16 |
| JP2025111591A (ja) | 2025-07-30 |
| AU2020384066B2 (en) | 2025-10-30 |
| CN118955495A (zh) | 2024-11-15 |
| WO2021096238A1 (en) | 2021-05-20 |
| JP7671751B2 (ja) | 2025-05-02 |
| KR20210059632A (ko) | 2021-05-25 |
| EP4041733A1 (en) | 2022-08-17 |
| EP4041733B1 (en) | 2024-05-08 |
| EP4041733A4 (en) | 2023-08-30 |
| MX2022005679A (es) | 2022-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL4041733T3 (pl) | Pochodne mające ugrupowanie 2,3-dihydro-1h-indenu lub 2,3-dihydrobenzofuranu lub ich farmaceutycznie dopuszczalne sole oraz kompozycje farmaceutyczne je zawierające | |
| CY1124496T1 (el) | Οξυστερολες και μεθοδοι χρησης αυτων | |
| PH12020500446A1 (en) | Bisamide sarcomere activating compounds and uses thereof | |
| CY1119357T1 (el) | Φαρμακευτικες συνθεσεις που περιλαμβανουν συνδετες υποδοχεων σιγμα | |
| DK3999038T3 (da) | Orale formuleringer af en kardial sarcomer-inhibitor | |
| BR112017020081A2 (pt) | análogos deuterados de etifoxina, seus derivados e usos dos mesmos | |
| EP3849541A4 (en) | 2,3-dihydrobenzo[b]thiophene derivatives as hypoxia inducible factor-2(alpha) inhibitors | |
| HRP20240643T1 (hr) | Heterociklički spojevi za inhibiciju aktivnosti tyk2 | |
| EP4041734C0 (en) | DERIVATIVES HAVING A 1,2,3,4-TETRAHYDRONAPHTHALENE FRACTION OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | |
| EA202092829A1 (ru) | Композиции тофацитиниба с контролируемым высвобождением | |
| EP4135699A4 (en) | Pharmaceutical compositions | |
| MX383577B (es) | Derivados sustituidos de guanidina. | |
| EP3917926A4 (en) | IMIDAZOCHINOLINE AMINE DERIVATIVES, PHARMACEUTICAL COMPOSITION, USE THEREOF | |
| CO2020011860A2 (es) | Compuestos de 4–metildihidropirimidinona y su uso farmacéutico | |
| BR112022007207A2 (pt) | Composição farmacêutica que compreende selexipag | |
| EP3914362C0 (en) | Exercise machine | |
| KR102474935B9 (ko) | 파에오놀 및 판테놀 또는 이들의 약학적으로 허용가능한 염을 유효성분으로 포함하는 약학적 조성물 | |
| SA521421354B1 (ar) | مركبات مفيدة في صورة مُعدِّلات الالتهام الذاتي الذي تتوسط فيه شابرون | |
| PL3746441T3 (pl) | Związek farmaceutyczny, jego sole, jego preparaty oraz sposoby ich wytwarzania i zastosowania | |
| EP3947172A4 (en) | PACKAGING STRUCTURES | |
| IL283105A (en) | Combination of MCL-1 inhibitor and midostearoin, its uses and pharmaceutical preparations | |
| IL280639A (en) | History of thiazoles and their pharmaceutically acceptable salts | |
| IL240136A0 (en) | Pharmaceutical preparations containing n-[3-chloro-4-(3-fluorobenzyloxy)phenyl]-6-[5({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]quinazolin-4-amine or salt Pharmacists accept, solvate or its dissolved salt | |
| EP3790664A4 (en) | ROTATING SPRINKLER | |
| KR102182651B9 (ko) | 4--N--1H-피라졸로[3,4-b]피리딘-3-일)벤즈아미드 유도체, 또는 이의 약학적으로 허용 가능한 염의 미백용 소재 용도 |